Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients

dc.contributor.authorHiwase, D.
dc.contributor.authorYeung, D.
dc.contributor.authorWhite, D.
dc.date.issued2011
dc.description.abstractLong-term follow-up of clinical studies has demonstrated the efficacy of imatinib therapy in newly diagnosed chronic phase-chronic myeloid leukemia patients (CML). However, recent updates of two separate randomized Phase III studies demonstrated higher complete cytogenetic and major molecular response rates with dasatinib and nilotinib compared with imatinib 400 mg/day. Hence, for newly diagnosed chronic phase-CML patients there are multiple treatment options, including standard-dose imatinib, high-dose imatinib, and combination therapy of imatinib and interferon, dasatinib and nilotinib. This article critically analyzes the current literature and provides guidelines for the management of newly diagnosed CML. Disease and therapy-related prognostic factors, which may aid in the selection of therapeutic strategies to enable optimal treatment outcomes, are discussed. In addition, we provide commentary on the therapeutic options for patients who fail imatinib therapy.
dc.description.statementofresponsibilityDevendra K Hiwase, David T Yeung and Deborah L White
dc.identifier.citationExpert Review of Hematology, 2011; 4(3):285-299
dc.identifier.doi10.1586/ehm.11.19
dc.identifier.issn1747-4086
dc.identifier.issn1747-4094
dc.identifier.orcidHiwase, D. [0000-0002-6666-3056]
dc.identifier.orcidYeung, D. [0000-0002-7558-9927]
dc.identifier.orcidWhite, D. [0000-0003-4844-333X]
dc.identifier.urihttp://hdl.handle.net/2440/68381
dc.language.isoen
dc.publisherExpert Reviews Ltd
dc.rights© 2011 Expert Reviews Ltd.
dc.source.urihttps://doi.org/10.1586/ehm.11.19
dc.subjectCML
dc.subjectdasatinib
dc.subjectimatinib
dc.subjectnilotinib
dc.subjectTKI
dc.titleOptimizing the selection of kinase inhibitors for chronic myeloid leukemia patients
dc.typeJournal article
pubs.publication-statusPublished

Files